

FFI and GSS are also inherited by autosomal dominance. Both are very rare, with no more than 10 known families with FFI and 50 with GSS [30, 31]. GSS, unlike other PrD, may have a longer clinical course [32]. It is characterised by missense mutations of the *Prnp* gene, by specific neuropathological lesions and multicentric amyloid plaques.

The most recently recognized form of PrD in humans, new variant CJD (vCJD), was first described in 1996 as linked to BSE [33]. What distinguishes vCJD from sporadic cases is that the age of patients is much lower (vCJD age range 19-39 years, versus sCJD age range 55-70 years) and the duration of illness is longer (vCJD 7.5-22 months, versus sCJD 2.5-6.5 months). Variant CJD displays a distinct pathology characterised by abundant florid plaques surrounded by vacuolation [34]. Most cases of vCJD have been observed in the UK. In addition, all investigated cases of vCJD showed homozygosity of methionine at codon 129 [35, 36].

The clinical features of PrD are extremely heterogeneous and may include rapidly progressive dementia, psychiatric symptoms (mostly in vCJD, less in CJD), cerebellar syndrome (in kuru, GSS, CJD), movement disorders (myoclonus, dystonia, chorea, mostly in vCJD), encephalopathy (in CJD), pyramidal signs, cortical blindness, and sensory symptoms (hyperpathia, mostly in vCJD) [26, 32, 37, 38].

Treatment options in prion disease

PrD are still uniformly fatal, some within weeks to months from diagnosis, while vCJD patients may survive for more than a year, and GSS patients for up to 6 years. No specific treatments for PrD are known, although some prophylactic and neuroprotective agents have been proposed on the basis of cell culture experiments and animal studies [39-42]. Animal studies indicate that substantial neuropathological changes in PrD are already present before the onset of symptoms and are spatially related to PrP^{sc} deposits. Ideally, an effective intervention should start during the preclinical stage of disease, and be aimed at preventing PrP^{sc} neuroinvasion or propagation in the CNS. Unfortunately, no tests are available currently to detect asymptomatic PrD, except for carriers of pathogenic mutations of the *Prnp* gene.

Inhibition of PrP^{sc} formation may be achieved, at least in laboratory experiments, through one of the following strategies:

- Abrogation of PrP^c synthesis or prevention of its transport to the cell surface
- Stabilisation of the PrP^c structure to make its conformational change unfavourable

- Sequestration of PrP^{sc}
- Reversion of PrP^{sc} to a protease-sensitive form
- Interference with the interaction between PrP^c, PrP^{sc}, and other macromolecules involved in the conversion process (for review see [43]).

However, most compounds that have shown some effectiveness in cell culture or in animal models of PrD only work when administered at the time of infection or shortly thereafter. The heterogeneity and complexity of PrD suggest that a combination of several compounds with different modes of action may be necessary for their prevention and treatment. Preclinical diagnostic tests for PrD are urgently needed and deemed crucial in the success of an early treatment.

Antibiotics, dyes, and NMDA receptor ligands

The polyene macrolide antibiotic, amphotericin B [44, 45], and its less toxic derivative, MS-8209 [46], have been shown to delay scrapie agent propagation and PrP^{sc} accumulation in mice or hamsters. The amyloid-binding dye, Congo red, is able to inhibit PrP^{sc} accumulation and replication, most likely by overstabilising the abnormal conformational isoform [47, 48]. The anthracycline 4-iodo-4-deoxy- doxorubicin has been found to delay hamster scrapie progression via binding to amyloid fibrils [49]. Suramin, a highly sulphated urea based compound, and dapsone, a sulphone, were also tested against mouse scrapie and found to increase the incubation period when given continuously [50, 51]. Porphyrins and phthalocyanins as sulphated forms also were shown to inhibit the production of PrP^{sc} in neuroblastoma cell cultures [52, 53].

The neurotoxic effect displayed by PrP^{sc} and its fragments was found to be prevented *in vitro* by antagonists of NMDA receptor channels, such as memantine [17, 54]. Moreover, flupirtine, a triaminopyridine compound clinically used as non-opioid analgesic drug, which acts like an NMDA receptor antagonist, but does not bind to the receptor, was found to display a strong cytoprotective effect on neurons treated with PrP^{sc} or with a toxic fragment [54, 55]. A double-blind placebo-controlled study has been carried out in 28 CJD patients [56]. Patients treated with flupirtine showed significantly less cognitive changes (dementia) than placebo patients, which led the authors to conclude that flupirtine may have beneficial effects on the cognitive function of patients with CJD [56]. The study did not investigate other aspects of neurological deterioration in progressive CJD, the results appear therefore of limited usefulness.

Active and passive immunisation

Several studies have suggested that antibodies (Ab) might have beneficial anti-prion properties in infected cells [42, 57]. Auto-antibodies can be induced in PrP^c-expressing mice and have the potential to cure cells after prion infection [58, 59]. Furthermore, in transgenic mice expressing both PrP^c and a defined anti-PrP^c antibody, prion infectivity within the spleen is significantly reduced [60]. Peretz et al. (2001) investigated seven different recombinant antibodies raised to various parts of the normal PrP^c protein [61]. They exposed a mouse neuroblastoma cell line (ScN2a) infected with PrP^{sc} to varying concentrations of each Ab and measured the amount of PrP^{sc} protein. The most potent Ab prevented conversion of PrP^c to PrP^{sc} and also cleared pre-existing PrP^{sc} in a dose-dependent manner. Removal of Ab after 2 weeks of treatment left cultures free of prion infectivity for an additional 4 weeks [61].

Recent work by White et al. (2003) suggested that another approach, passive application of anti-PrP^c antibodies, could be effective [62]. Monoclonal antibodies (mAb) were generated in non-tolerant PrP^c-knockout mice and exhibited different specificities towards PrP^c and PrP^{sc}. Mice were infected with PrP^{sc} by the intraperitoneal (i.p.) or intracerebral routes (i.c.), and mAb were injected i.p. twice per week, starting a few weeks after infection. In mice infected with prion by the i.p. route, mAb treatment produced a dose and time dependent reduction in PrP^{sc} and prion infectivity, and a significant prolongation of survival. Interestingly, the largest effects were obtained with the mAb mainly reacting with PrP^c. However, the protective effect of mAb was only observed when prions were applied by the i.p. route, whereas prion infections caused by i.c. inoculation were not influenced by mAb treatment. This suggested that the antibody cannot cross the blood-brain barrier at a sufficient concentration to exert a protective function [62].

It remains however unclear whether the above findings in cell culture and mice are transferable to humans, given the fact that the exact mode and time point of prion infection are usually unknown. In addition, in most of the mouse studies, a very high dose of mAb was applied in a continuous fashion (for review see [42]), which may produce allergic reactions and also result in inactivating antibodies in human patients.

Quinacrine and chlorpromazine

The antimalarial drug quinacrine (mepacrine), a cyclic tetrapyrrole, and the antipsychotic chlorpromazine (Figure 1) were shown to prevent the conversion of PrP^c to PrP^{sc} in cell culture. Doh-ura et al. (2000) reported that lysosomotropic agents (e.g. quinacrine or chloroquine) inhibited protease-resistant prion protein accumulation in scrapie-infected murine neuroblastoma cells (ScNB). The inhibition occurred without apparent effects on normal PrP^c biosynthesis or turnover, and without direct interactions with prion protein molecules [63]. Similar effects of quinacrine were reported later by Korth et al. (2001). These authors cultured mouse neuroblastoma cells (ScN2a) infected with PrP^{sc} to show that 6 days of treatment with quinacrine or chlorpromazine was able to reduce the conversion of PrP^c to PrP^{sc} [64].




Figure 1. Chemical structure of quinacrine and chlorpromazine

Quinacrine has been used in humans for over 60 years to treat malaria, and can be administered orally at high doses on a daily basis. The currently suggested oral dose for CJD patients is however higher than the antimalarial dose and may produce significant side effects in a considerable proportion of the treated patients. Chlorpromazine, although less potent than quinacrine in cell culture, crosses the blood-brain barrier to a larger extent.

Turnbull et al. (2003) showed that quinacrine also may act as an effective antioxidant, readily scavenging hydroxyl radicals generated during incubation of toxic PrP^{sc} fragments with murine neurons [65]. Quinacrine also significantly reduced toxicity of the PrP¹⁰⁶⁻¹²⁶ peptide fragment in these cells. On the other hand, Collins et al. (2002) evaluated oral quinacrine in mice infected with PrP^{sc}, but were not able to demonstrate any significant effect of the drug on overall survival of treated animals compared to controls [66]. Barret et al. (2003) also examined the efficacy of quinacrine and chlorpromazine in different *in vitro* models and in an experimental murine

model of BSE [67]. Despite the inhibition of PrP^{sc} accumulation in ScN2a cells, quinacrine was unable to produce a detectable effect in the animal model.

Japanese researchers are carrying out an ongoing clinical study of oral quinacrine in patients with sporadic and iatrogenic CJD. Results in the first 4 patients have been published recently [68]. Quinacrine (300 mg/d) has been administered for 3 months. Improved arousal level of patients with akinetic mutism, and restored eye contact or voluntary movements in response to stimuli were described. Clinical improvement was however transient, lasting 1-2 months. Quinacrine at the above dose caused liver dysfunction and skin pigmentation in all cases [68]. Further results in a larger patient population should be presented in near future.

A prospective clinical study of quinacrine in PrD, the PRION-1 study [69], is currently enrolling patients in the UK (Figure 2). Patients aged 12 years and older with all types of PrD are eligible. The study protocol features a partially randomised design, with patients who opt for quinacrine treatment split in two arms according to their preference for immediate vs. deferred (by 24 weeks) treatment. Treated patients will receive a loading dose of quinacrine (1 g on the first day), followed by 300 mg/d as a long term dose. The primary efficacy endpoints are mortality and the proportion of responders overall and at 24 weeks. Response is defined as independently rated lack of deterioration, global impression of change (based on the Clinician's Interview Based Impression of Change, CIBIC-plus), and patients score on the Brief Psychiatric Rating Scale (BPRS). Secondary efficacy endpoints are neurological and neuropsychological changes, including changes in markers of disease activity, MRI, and EEG [69].

Routine follow-up will be identical for all patients participating in the PRION-1 trial, with the exception of patients with inherited PrD, who have longer disease duration and will be followed up less frequently. Follow-up assessments are taking place monthly for the first 6 months, then every 3 months until end of study. Assessments will include medical history, physical examination, liver function and blood clotting, neurological examination recorded on video, and a series of neurological assessments. The study accrual target is 160 patients. Currently 18 patients have been enrolled [69].




Figure 2. Flow chart of the PRION-1 trial of quinacrine in patients with PrD [69].

Polysulphonated glycosides (glycans)

Several polysulphonated polysaccharides, including pentosan polysulphate (PPS) (Figure 3) and dextran sulphate (DS), have been shown to prolong the incubation period in PrP^{sc} infected rodents if given before infection [70-72], and to inhibit PrP^{sc} accumulation in neuroblastoma cells [73]. The effects of these polyanions may be due to an inhibition of the formation of PrP fibrils [74] or to reduction of the amount of PrP^c on the cell surface by stimulating

endocytosis of PrP^c [52]. Sulphonated polyglycosides are not known to penetrate the CNS, and hence the first attempts to demonstrate their effects were made in peripheral organs [75].

Caughey and Raymond (1993) tested various polysulphonated glycosides (PG) and found PPS, carrageenan, and dextran sulphate 500 (DS500) to be highly active in the inhibition of PrP^{sc} production [73]. PPS was most active, showing half of its maximal activity at 1 ng/ml. Shyng et al. (1995) reported PPS and related compounds to cause a decrease of PrP^c on the surface of cultured chicken and mouse neuroblastoma cells. PPS caused a redistribution of PrP^c from the surface to the interior of the cell (intracellular late endosomes). The differences in the binding strength of PrP^c to PPS and to other PG were found to parallel their *in vivo* and *in vitro* anti-PrP^{sc} formation potency [52]. Ehlers and Diringer (1984) inoculated mice i.p. or i.c. with scrapie agent and treated them systemically with DS500 [76]. None of the i.c. inoculation experiments were affected by the treatment. With i.p. inoculations, however, it was seen that DS500 did decrease (by approximately one order of magnitude) the infectivity found in the spleen at various times after single injection of the drug, and significantly prolonged incubation times. Treated mice also showed a significant increase in the mean incubation period compared with controls. It was noted that DS500 remained in the body of an inoculated mouse for up to 7 months. A maximum effect was seen when the drug was given at the same time with the infection, and no effect was seen when it was given 35 days after infection [76].




Figure 3. Chemical structure of pentosan polysulphate (PPS)

This work was followed by the study of Farquhar and Dickinson (1986), who carried out a series of murine experiments to inoculate i.p. scrapie [75]. This was associated, at various times before and after the scrapie inoculum, with various quantities of DS500 as a single i.p. injection. It was found that DS500 reliably increased the incubation period of the disease, and that this did not seem to depend on the strain of disease or the inbred strain of mouse

used. The effect seemed to be present when DS500 was given up to 4 weeks before and up to 3 weeks after the scrapie inoculum. The incubation period was extended by 5-19% at this dose, but if increased doses of DS500 were used, the incubation period could be prolonged by up to 62% [75]. Kimberlin and Walker (1986) gave various inocula of scrapie to mice either i.v. or i.p., and various drugs were tested before or after the scrapie infection [77]. DS500 proved effective in reducing the titre of the scrapie inoculum. Little effect was seen with heparin, dextran, or DEAE dextran. Diringer and Ehlers (1991) inoculated mice i.p. with scrapie and administered PPS i.p. on different days (84 to 50) before the PrP^{sc} infection. PPS increased the incubation period of mice by up to 75% [70]. Hamsters were also inoculated i.p. with various quantities of DS500 or PPS and with scrapie, separated by 2 to 24 hrs [78]. As the dose of DS500 increased, the incubation period also increased, but the maximum achieved with non-toxic doses of the drug was 21%. It was noted that a single i.p. administration of PPS increased the incubation period of i.c. inoculated scrapie by around 18% [78]. Farquhar et al. (1999) injected i.p. PPS immediately after scrapie infection of mice. Depending on mouse strain, a single PPS dose of 250 mg increased the scrapie incubation period by up to 66%. A single 1 mg i.p. dose of PPS protected mice completely from simultaneous scrapie infection. On the other hand, oral PPS was ineffective in delaying disease [79].

Doh-ura et al. (2004) recently infected transgenic mice (Tg7) expressing hamster prion protein with i.c. scrapie, and different agents were infused cerebroventricularly starting on day 10 or day 35 after infection [80]. The infusion was continued for 4 weeks. Infused drugs included lysosomotropic chemicals, such as E-64d cysteine protease inhibitor, chloroquine, quina-crine, amphotericin B, and PPS. Lysosomotropic agents demonstrated marginal effects in prolonging the incubation time when administered on day 35 after infection, and either no effect or less effect at the earlier stage (day 10 after infection). Amphotericin B and PPS demonstrated remarkable effects either early or late in the disease course. Amphotericin B resulted in around 30% prolongation of the incubation time when administered at the early stage, and 12% prolongation at the late stage. PPS showed more beneficial effects than amphotericin B, and mice which received PPS at the early stage survived 173% longer, and at the late stage 92% longer. Maximal effects of PPS at a later stage (day 42 of infection) were obtained at 230 $\mu\text{g}/\text{kg}/\text{day}$. Analysis of detailed relationship between the initiation time of the infusion of PPS and the outcome revealed that the effects of PPS were quite dependent on the timing of infusion initiation, with earlier initiation of treatment rendering a better prognosis [80]. Analysis by either immunohistochemistry or immunoblotting demonstrated that PPS potently inhibited PrP^{sc} deposition in the brain. It also showed that amount or dis-

tribution of deposited PrP^{sc} in the brain of mice treated with PPS was modified and did not return to the same level observed in the control animals, even when they were at a terminal stage. Immunohistochemical analysis demonstrated that mice treated with PPS from the early stage did not show any PrP^{sc} deposits in the brain on day 52. On the other hand, control animals demonstrated PrP^{sc} deposits in the parahippocampal white matter on day 35, and later also in the thalamus. No notable adverse effects were observed in experimental mice treated with up to 230 $\mu\text{g}/\text{kg}/\text{day}$ intraventricular PPS for two months. In a separate set of experiments in normal dogs, higher doses, such as 345 $\mu\text{g}/\text{kg}/\text{day}$ and 460 $\mu\text{g}/\text{kg}/\text{day}$, did show adverse effects such as partial or generalized epileptic seizures, which began within 24 hours after PPS infusion at the above high doses was initiated [80].

Both heparin and PPS are rapidly taken up into RES cells by a saturatable pathway. Low doses are cleared quickly into the RES, whereas higher doses saturate the RES and are excreted in urine [81]. PPS is metabolised by cellular non-specific desulphation in many organs and tissues, including vascular endothelium [82]. Renal excretion of desulphated PPS from plasma takes place over 6 days following a single dose, which also involves partial polyxylose chain breakdown. PPS can be administered orally, but only a low proportion (0.5-4%) of the drug is detected in the blood circulation [83, 84]. When PPS is given orally, anti-inflammatory effects are seen in the bladder after long-term administration [85]. It is considered that this is due to accumulation of the drug in cells of the RES with slow break-down and excretion. When used for anticoagulation and given s.c. or i.v., PPS may cause an early, benign, reversible thrombocytopenia and a rise in lipoprotein lipase activity [83]. Similarly to heparin, a rare, immune, severe form of thrombocytopenia has been also reported [86]. No significant neurological symptoms or signs have been reported in humans or animals treated orally or parenterally with PPS.

There has been no penetration in the CNS demonstrated with peripherally administered PPS, which is not surprising with the hydrophilic nature of the drug. On the other hand, direct intracerebral administration of PPS may afford high compartmental concentrations of the drug in the CNS, but no pharmacokinetics is available for this specific mode of administration. Direct administration of PPS to the CNS would be expected to allow PPS to concentrate inside cells, entering them via ubiquitous heparan-binding sites, and to exert biological effects on those cells infected by PrP^{sc}. In analogy to other therapeutic molecules, e.g. recombinant proteins delivered directly into the primate and human brain [87, 88], it is considered likely that cerebroventricular infusion of PPS may have the highest ratio of local versus systemic drug concentration.

Rationale for local administration of drugs to the CSF

The clinical and late preclinical phase of PrD with PrP^{sc} formation in the brain requires drugs that can cross into brain parenchyma and be present in the brain in a biologically active concentration [32, 42, 43]. However, in the early stages of PrD, with an intact blood-brain barrier (BBB), there is severe limitation of the penetration of drugs from blood into brain interstitium, and from there into glial and neuronal cells. Even at late stages of the disease, tight junctions of the brain capillaries may remain at least partially intact and therefore selectively limiting the entry of most molecules.

Compounds that are highly lipid soluble, such as alcohol, barbiturates, and some anticonvulsants, may easily pass through the endothelial cells forming the inner layer of the BBB. Lipid solubility is measured by the oil/water (octanol/water) partition coefficient, and molecules with a high coefficient usually permeate efficiently the BBB (for review see [89]). Such highly lipid soluble compounds with a high partition coefficient are phenytoin and methadone, and they cross the BBB in large quantities under normal conditions. Not all lipid soluble molecules, however, easily traverse the BBB. Compounds highly bound to plasma proteins have restricted access to the brain. For these substances, the degree of dissociation of the protein complex in transit through the capillary bed determines the degree of penetration across the BBB. Furthermore, there are special transport systems responsible for enhanced passage of certain compounds with low lipid solubility across the BBB, such as the physiologically important molecules D-glucose and phenylalanine [90]. The BBB can be subjected to pharmacological or osmotic modifications aimed at temporarily increasing its permeability to certain therapeutic molecules. These approaches are however invasive and have the potential for serious side effects [91, 92].

The CSF-brain barrier (CBB) seems to be more permeable because of its anatomical structure lacking tight junctions between the neuroependymal cells lining the cerebral ventricles. Substances administered to the CSF have been shown to penetrate into brain tissue by diffusion. The physical process of diffusion is gradient-driven, and penetration of the CBB will be enhanced by higher concentration of a molecule in one compartment [93, 94]. This fact points at an important advantage of the local application of drugs to the CSF - high local concentration in the CNS compartments, as opposed to negligible systemic concentration due to low reabsorption in the blood stream.

Continuous CSF circulation is physiologic process which lends itself to dissemination of substances throughout the CNS. CSF is continuously produced and completely replaced in the brain approximately every 8 hours.

In normal adults, the rate of CSF removal by reabsorption is equal to the rate of CSF production by filtration of blood through the intraventricular choroid plexus. CSF circulates from the sites of production, the lateral ventricles and third ventricle, into the cerebral aqueduct and into the fourth ventricle. From there CSF escapes the internal ventricular system of the brain by the foramina of Luschka and Magendie into the subarachnoid space around the brain and the spinal cord. Arachnoid granulations and dural sinuses are the route for CSF reabsorption to the blood circulation [95].

Animal models support findings in humans. In a model of cerebroventricular infusion in rats, radioactive sucrose was infused into one lateral ventricle. Within minutes after infusion, sucrose moved into the third ventricle, the aqueduct, fourth ventricle, and the subarachnoid space of the quadrigeminal, ambient and interpeduncular cisterns. About 15% of the injected sucrose entered these large cisterns. In contrast to most other CSF-brain interfaces, little sucrose moved from CSF into the medulla next to the lateral recesses and tissues adjacent to the large CSF cisterns. A thick, multilayered *glia limitans* visible on electron micrographs seemed to form a CSF-brain barrier at these interfaces [96].

Evidence exists also for the bulk flow of brain interstitial fluid via preferential pathways through the brain, which is closely related to CSF. This bulk flow of interstitial fluid has implications for drug delivery, drug distribution, and drug clearance [97].

Preliminary results with continuous long-term cerebroventricular administration of PPS in human PrD

The first objective of cerebroventricular PPS administration in PrD patients was to evaluate the short and long term safety and tolerability of escalating doses of PPS administered by continuous long term infusion. A secondary objective was to assess efficacy of PPS in delaying disease progression and improving existing neurological deficits. Patients with probable sporadic, iatrogenic, or variant CJD, or with hereditary syndromes such as GSS or FFI were eligible to receive PPS infusion. Informed consent was obtained where possible. If patients were not fit and able to consent, a legally appointed representative signed the consent forms. The primary endpoint of PPS administration studies was maximum tolerated dose of PPS as assessed by occurrence of serious toxicity resulting from PPS administration. Dose-limiting toxicity (DLT) was defined as any one of the following occurring in two or more patients:

- Any grade 4 toxicity attributed to PPS

- Grade 3 toxicity for neurological symptoms or for symptoms in other organ systems lasting longer than 5 days and attributed to PPS

Patients considered for PPS administration had to have a probable diagnosis of one of the above PrD in accordance to WHO criteria. Normal haematological, renal, and liver function was also a requirement. Because of the surgical procedure for implantation of the ventricular catheter and subcutaneous pump and infusion system, ongoing treatment with anticoagulants such as warfarin, heparin, clopidogrel, or aspirin was not allowed. Also the presence of any active infection or any viral syndrome within two weeks prior to treatment was an exclusion criterion.

Patients undergoing surgery had standard ventricular catheters placed in the anterior horn of the right lateral ventricle or in a few cases in both frontal horns, unless clinical reasons dictated another point of access to the ventricular system. In the first case with PPS administration, the catheter was connected initially to an external pump for trial administration of PPS, and later attached to a subcutaneously programmable pump (SynchroMed EL, 18 ml reservoir, with side port, Medtronic Inc.) (Figure 4) permanently implanted in the abdominal wall. Later cases had simultaneous implantation of the catheter system and the infusion pump in the same surgical session. After a period of time after the surgical procedure (3-14 days) in which the pump was not active and scar tissue formation was expected to occur, PPS infusion commenced at a low dose level. The decision to proceed to the next higher dose level was based on the absence of clinical side effects and on normal findings on non-enhanced CT scans (e.g. exclusion of hydrocephalus or intracranial blood).




Figure 4. The implantable externally programmable pump (SynchroMed EL with side port, Medtronic Inc., Minneapolis, MN) is shown with attached catheter (A). (B) shows a portable pump programming unit (telemetry unit) with printer.

There are no previously published data on a safe or potentially effective dose of cerebroventricularly infused PPS in human patients with PrD. Based on preclinical animal work, a dose escalation schedule was set up starting at 1 $\mu\text{g}/\text{kg}/\text{d}$ and escalating on a daily basis until a target dose of 11 $\mu\text{g}/\text{kg}/\text{d}$ was reached. This represented a 10-fold dose reduction, based on body surface area and weight differences, from the lowest effective PPS dose used in scrapie-infected mice in a preclinical study of intraventricular PPS [80]. The maximum daily dose of cerebroventricular PPS administered to the first 6 patients on a long term basis was 11 $\mu\text{g}/\text{kg}/\text{day}$. All further cases have received a maximum dose of 110 $\mu\text{g}/\text{kg}/\text{d}$ in 10-20 $\mu\text{g}/\text{kg}/\text{d}$ escalation steps, but long term follow up with this dose is still limited (Table 1).

The clinical source of PPS is *Pentosanpolysulfat SP54* in sterile 1 ml vials, supplied by the pharmaceutical company Bene Arzneimittel GmbH (Germany). Each vial contains 100 mg of Sodium-PPS (100 mg/ml) with 1% sodium-4-oxopentanoate as a stabiliser. For filling of the pump reservoir, PPS SP54 100 mg/ml is diluted with 0.9% NaCl to a final concentration of 1-10 mg/ml. The pump is then programmed to deliver the total daily dose in a continuous simple infusion mode (constant volume and infusion rate over time).

There are no standardised or widely accepted criteria for assessment of treatment efficacy in PrD. Surrogate criteria for efficacy were thus adopted and included overall survival, speed of disease progression before PPS infusion compared with disease progression after start of PPS, neuro-radiological imaging, and changes in the general and neurological condition of the patients.

The first patient to receive PPS infusion was a young man suffering from vCJD [98]. He presented initially with subjective signs of behavioural disturbance, followed a few months later by progressive ataxia, pyramidal signs and myoclonus, which led to the clinical diagnosis of possible vCJD. The clinical picture combined with abnormal MR findings in the FLAIR sequence (pulvinar sign) and positive tonsil biopsy allowed the diagnosis of probable vCJD 8 months after the occurrence of initial clinical symptoms. At the time of first administration of PPS, the patient had symptoms of advanced vCJD, such as ataxia, dementia, dysphagia, dysphasia, myoclonus, and was confined to bed and unable to care for himself. He was fed via percutaneous gastrostomy. The initial PPS dose of 1 $\mu\text{g}/\text{kg}/\text{d}$ was escalated without drug-related complications to the target dose of 11 $\mu\text{g}/\text{kg}/\text{d}$. Continuous infusion of PPS for 23 months has not caused any drug-related side effects. Cerebroventricular PPS at the above dose did not have any measurable systemic anticoagulant activity in serum, as confirmed by unchanged INR (international normalised ratio) before and during PPS infu-

sion. Follow-up CT scans demonstrated no intracerebral haemorrhage, and there were no seizures. Subdural fluid collections first over the right hemisphere and subsequently over the left hemisphere necessitated surgical (burr hole) evacuation of fluid. Repeated surgical revisions of the fluid collections were necessary (Figure 5).

This first patient is currently alive and in a stable condition. Although there were no major improvements in the neurological and general condition, there were a few notable changes. The patient is now able to fix his eyes on persons, to obey simple one stage commands, and to make verbalization attempts in response to stimuli. The sleep/wake cycle and the reflex swallow are restored and the myoclonus is reduced. The patient has gained 5 kg of weight compared to pre-PPS baseline, while on the same nutritional regime. Regular follow-up CT scans have shown progressive brain atrophy during PPS administration, which could not be correlated to any worsening of the clinical condition (Figure 5).

Since January 2003, a total of 13 patients with PrD have undergone surgery and continuous cerebroventricular administration of PPS. Anonymised clinical and follow-up data are presented in Table 1. The most important clinical finding is the safety of PPS administration to the cerebral ventricles. The maximum tolerated dose of PPS has not been reached. There were no cases with side effects attributable to PPS, even in patients receiving $110 \mu\text{g}/\text{kg}/\text{d}$ of PPS.

Focal seizures have been observed in one patient on $11 \mu\text{g}/\text{kg}/\text{d}$, and generalised tonic-clonic seizures in one patient with $110 \mu\text{g}/\text{kg}/\text{d}$. It remains to be clarified if these seizures were a side effect of PPS or of surgery, since in both cases they occurred months after start of PPS and during infusion with a stable dose of PPS.

It is currently unclear if a higher dose of PPS has a stronger effect, and if dose escalation should be continued above $110 \mu\text{g}/\text{kg}/\text{d}$. In most cases it seems that PPS administration results in a temporary halt of disease progression, but this conclusion is not based on hard evidence or objective measurements. PPS administration seems not able to reverse the clinical course of advanced disease and to achieve functional recovery of established neurological deficits.

Furthermore, surgery in the brain affected by PrD may result in a higher rate of surgical complications than usually encountered in comparable non-PrD cases. Brain atrophy may progress while PPS is administered, and there is no apparent correlation between degree of atrophy and clinical status of the patients. Therefore, in accordance with results from the pre-clinical animal studies [80], cerebroventricular infusion of PPS should be commenced as early as possible after disease diagnosis and, if possible, before the occurrence of fixed neurological deficits.

In conclusion, despite the encouraging preliminary results in PrD patients receiving long term cerebroventricular PPS, further clinical, neuro-radiological and laboratory investigations in the context of a prospective clinical study will be essential for the evaluation of genuine clinical benefits of PPS administration.




Figure 5. Serial CT scans of patient #1 demonstrating sequential occurrence of right parietal subdural fluid collection (upper right, arrows) and left parietal subdural collection (lower right, arrows). Note the progression of brain atrophy over time.

Table 1. Summary of clinical data of all current patients with PPS administration.

Patient number	Sex	Age at Dx ^a (years)	Diagnosis and clinical course after start of PPS	Survival (months after Tx ^a)	Maximum PPS dose ($\mu\text{g}/\text{kg}/\text{d}$)
1	M	17	vCJD. Stable disease, swallowing and myoclonus improved, brain stem function improved. PPS started at very advanced stage of disease.	23	11
2	M	19	sCJD. Initially neurological improvement, later slow progression. Weight gain 10 kg. Reduction of myoclonus. Partial seizures occurring a few months after start of PPS, currently on phenytoin.	10	11
3	F	12	vCJD. Stable disease, wheelchair bound. Currently speech deficit, stable weight, swallowing remained intact.	13	11
4	M	15	vCJD. Stable after PPS, but disease progressed rapidly before PPS started.	9	11
5	F	34	GSS Stable disease, but surgical complications (brain haemorrhage) giving rise to neurological deficits.	10	11
6	F	32	GSS Stable disease. Initially only very mild neurological symptoms present.	3	11
7	M	37	Iatrogenic CJD (GH ^b administration) Cerebellar syndrome, initially stable condition. Rapid deterioration despite PPS.	6	110
8	F	27	Iatrogenic CJD (GH ^b administration) Stable disease, but rapid progression before start of PPS. Alive but in state of limited awareness.	9	110
9	F	39	vCJD. Presented with psychiatric syndrome. Continuous neurological deterioration while on PPS. Generalized seizures occurring 2 months after start of PPS. Died of disease progression.	4 ^c	110
10	M	44	GSS Continued neurological deterioration. Increase in mental symptoms and disorientation while on PPS.	4	110
11	M	34	Iatrogenic CJD (GH ^b administration) Stable disease.	1	110
12	F	39	GSS Mild neurological deficits at start of PPS.	- ^d	110
13	F	66	sCJD	- ^d	110

^a - Dx/Tx - Diagnosis/Therapy.

^b - Growth hormone.

^c - Patient deceased.

^d - Follow-up period < 1 month.

References

1. Prusiner SB (1994) Biology and genetics of prion diseases. *Annu Rev Microbiol* 48:655-686
2. Vorberg I, Priola SA (2002) Molecular basis of scrapie strain glycoform variation. *J Biol Chem* 277: 36775-36781
3. Harris DA (2001) Biosynthesis and cellular processing of the prion protein. *Adv Protein Chem* 57:203-228
4. Dormont D (2002) Prions, BSE and food. *Int J Food Microbiol* 78:181-189
5. Brown DR (1999) Prion protein peptide neurotoxicity can be mediated by astrocytes. *J Neurochem* 73:1105-1113
6. Collinge J, Whittington MA, Sidle KC, Smith CJ, Palmer MS, Clarke AR, Jefferys JG (1994) Prion protein is necessary for normal synaptic function. *Nature* 370:295-297
7. Weissmann C, Bueler H, Fischer M, Sailer A, Aguzzi A, Aguet M (1994) PrP-deficient mice are resistant to scrapie. *Ann NY Acad Sci* 724:235-240
8. Prusiner SB (1998) Prions. *Proc Natl Acad Sci USA* 95:13363-13383
9. Weissmann C, Raeber AJ, Montrasio F, Hegyi I, Frigg R, Klein MA, Aguzzi A (2001) Prions and the lymphoreticular system. *Philos Trans R Soc Lond B Biol Sci* 356:177-184
10. Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y, Marino S, Weissmann C, Aguzzi A (1996) Normal host prion protein necessary for scrapie-induced neurotoxicity. *Nature* 379:339-343
11. Clarke AR, Jackson GS, Collinge J (2001) The molecular biology of prion propagation. *Philos Trans R Soc Lond B Biol Sci* 356:185-195
12. Caughey B (2003) Prion protein conversions: insight into mechanisms, TSE transmission barriers and strains. *Brit Med Bull* 66:109-120
13. Come JH, Fraser PE, Lansbury PT Jr (1993) A kinetic model for amyloid formation in the prion diseases: importance of seeding. *Proc Natl Acad Sci USA* 90:5959-5963
14. Cohen FE, Pan KM, Huang Z, Baldwin M, Fletterick RJ, Prusiner SB (1994) Structural clues to prion replication. *Science* 264:530-531
15. Huang Z, Prusiner SB, Cohen FE (1996) Scrapie prions: a three-dimensional model of an infectious fragment. *Fold Des* 1:13-19
16. Deleault NR, Lucassen RW, Supattapone S (2003) RNA molecules stimulate prion protein conversion. *Nature* 425:717-720
17. Brown DR, Schmidt B, Kretzschmar HA (1996) Role of microglia and host protein in neurotoxicity of a prion protein fragment. *Nature* 380:345-347
18. Brown DR, Kretzschmar HA (1997) Microglia and prion disease: a review. *Histol Histopathol* 12:883-992
19. Aguzzi A, Klein MA, Musahl C, Raeber AJ, Blattler T, Hegyi I, Frigg R, Brandner S (1998) Use of brain grafts to study the pathogenesis of prion diseases. *Assays Biochem* 33:133-147
20. Rezaie P, Lantos PL (2001) Microglia and the pathogenesis of spongiform encephalopathies. *Brain Res Brain Res Rev* 35:55-72

21. Brown DR (1999) Prion protein peptide neurotoxicity can be mediated by astrocytes. *J Neurochem* 73:1105-1113
22. Raeber AJ, Race RE, Brandner S, Priola SA, Sailer A, Bessen RA, Mucke L, Manson J, Aguzzi A, Oldstone MB, Weissmann C, Chesebro B (1997) Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. *EMBO J* 16:6057-6065
23. Giese A, Brown DR, Groschup MH, Feldmann C, Haist I, Kretzschmar HA (1998) Role of microglia in neuronal cell death in prion disease. *Brain Pathology* 8:449-457
24. Heppner FL, Aguzzi A. Prion Diseases. In: *Nature Encyclopedia of Life Sciences*. London: Nature Publishing Group. <http://www.els.net/> [doi:10.1038/npg.els.0000428]
25. Kubler E, Oesch B, Raeber AJ (2003) Diagnosis of prion diseases. *Br Med Bull* 66:267-279
26. Knight R (1998) Creutzfeldt–Jakob disease: clinical features, epidemiology and tests. *Electrophoresis* 19:1306-13010
27. Gambetti P, Parchi P, Petersen RB, Chen SG, Lugaresi E (1995) Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical, pathological and molecular features. *Brain Pathol* 5:43-51
28. Brown P, Preece M, Brandel JP, Sato T, McShane L, Zerr I, Fletcher A, Will RG, Pocchiari M, Cashman NR, d'Aignaux JH, Cervenakova L, Fradkin J, Schonberger LB, Collins SJ (2000) Iatrogenic Creutzfeldt-Jakob disease at the millennium. *Neurology* 55:1075-1081
29. Smith PG (2003) The epidemics of bovine spongiform encephalopathy and variant CJD; current status and future prospects. *Bull World Health Organ* 81,123-130
30. Medori R, Tritschler HJ, LeBlanc A, Villare F, Manetto V, Chen HY, Xue R, Leal S, Montagna P, Cortelli P (1992) Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. *N Engl J Med* 326:444-449
31. Fiorino AS (1996) Sleep, genes and death: fatal familial insomnia. *Brain Res Brain Res Rev* 22:258-264
32. Larner AJ, Doran M (2003) Prion diseases: update on therapeutic patents (1999-2002). *Exp Opin Ther Pat* 13:67-78
33. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG (1996) A new variant of Creutzfeldt-Jakob disease in the UK. *Lancet* 347:921-925
34. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H, Bostock CJ (1997) Transmission to mice indicate that 'new variant' CJD is caused by the BSE agent. *Nature* 389:498-501
35. Weissmann C, Aguzzi A (1997) Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease. *Curr Opin Neurobiol* 7:695-700
36. Ironside JW (2000) Pathology of variant Creutzfeldt-Jakob disease. *Arch Virol Suppl* 16:143-151

37. Spencer MD, Knight RSG, Will RG (2002) First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features. *Br Med J* 324:1479-1482
38. Wadsworth JD, Hill AF, Beck JA, Collinge J (2003) Molecular and clinical classification of human prion disease. *Br Med Bull* 66:241-254
39. Müller WEG, Laplanche JL, Ushijima H, Schroder HC (2000) Novel approaches in diagnosis and therapy of Creutzfeldt Jakob disease. *Mechanisms of Ageing and Development* 16:193-218
40. Head MW, Ironside JW (2000) Inhibition of prion-protein conversion: a therapeutic tool? *Trends Microbiol* 8:6-8.
41. Love R (2001) Old drugs to treat new variant Creutzfeldt-Jakob disease. *Lancet* 358:563
42. Gilch S, Schatzl HM (2003) Promising developments bringing prion diseases closer to therapy and prophylaxis. *Trends Mol Med* 9:367-369
43. Rossi G, Salmona M, Forloni G, Bugiani O, Tagliavini F (2003) Therapeutic approaches to prion diseases. *Clin Lab Med* 23:187-208
44. McKenzie D, Kaczkowski J, Marsh R, Aiken J (1994) Amphotericin B delays both scrapie agent replication and PrP-res accumulation early in infection. *J Virol* 68:7534-7536
45. Demaimay R, Race R, Chesebro B (1999) Effectiveness of polyene antibiotics in treatment of transmissible spongiform encephalopathy in transgenic mice expressing Syrian hamster PrP only in neurons. *J Virol* 73:3511-3513
46. Adjou KT, Demaimay R, Deslys JP, Lasmezas CI, Beringue V, Demart S, Lamoury F, Seman M, Dormont D (1999) MS-8209, a water-soluble amphotericin B derivative, affects both scrapie agent replication and PrPres accumulation in Syrian hamster scrapie. *J Gen Virol* 80:1079-1085
47. Caughey B, Race RE (1992) Potent inhibition of scrapie associated PrP accumulation by Congo Red. *J Neurochem* 59:768-771
48. Caspi S, Halimi M, Yanai A, Sasson SB, Taraboulos A, Gabizon R (1998) The anti-prion activity of Congo red. Putative mechanism. *J Biol Chem* 273:3484-3489
49. Tagliavini F, McArthur RA, Canciani B, Giaccone G, Porro M, Bugiani M, Lievens PM, Bugiani O, Peri E, Dall'Ara P, Rocchi M, Poli G, Forloni G, Bandiera T, Varasi M, Suarato A, Cassutti P, Cervini MA, Larsen J, Salmona M, Post C (1997) Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. *Science* 276:1119-1122
50. Manuelidis L, Fritch W, Zaitsev I (1998) Dapsone to delay symptoms in Creutzfeldt-Jakob disease. *Lancet* 352:456
51. Guenther K, Deacon RM, Perry VH, Rawlins JN (2001) Early behavioural changes in scrapie-affected mice and the influence of dapsone. *Eur J Neurosci* 14:401-409
52. Shyng SL, Lehmann S, Moulder K, Harris D (1995) Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein PrPc in cultured cells. *J Biol Chem* 270:30221-30229
53. Priola SA, Raines A, Caughey WS (2000) Porphyrin and phthalocyanine antiscrapie compounds. *Science* 287:1503-1506

54. Perovic S, Pergande G, Ushijima H, Kelve M, Forrest J, Muller WE (1995) Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. *Neurodegeneration* 4:369-374
55. Perovic S, Schleger C, Pergande G, Iskric S, Ushijima H, Rytik P, Muller WE (1994) The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-methyl-D-aspartate and gp120 of HIV-1. *Eur J Pharmacol* 288:27-33
56. Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, Irle E, Pergande G, Ellers-Lenz B, Windl O, Kretzschmar HA, Poser S, Prange H (2004) Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. *Neurology* 62:714-718
57. Enari M, Flechsig E, Weissmann C (2001) Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. *Proc Natl Acad Sci USA* 98:9295-9299
58. Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R, Meeker HC, Frangione B, Wisniewski T (2002) Immunization delays the onset of prion disease in mice. *Am J Pathol* 161:13-17
59. Gilch S, Wopfner F, Renner-Muller I, Kremmer E, Bauer C, Wolf E, Brem G, Groschup MH, Schatzl HM (2003) Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. *J Biol Chem* 278:18524-185231
60. Heppner FL, Musahl C, Arrighi I, Klein MA, Rulicke T, Oesch B, Zinkernagel RM, Kalinke U, Aguzzi A (2001) Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. *Science* 294:178-182
61. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, Mehlhorn IR, Legname G, Wormald MR, Rudd PM, Dwek RA, Burton DR, Prusiner SB (2001) Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. *Nature* 412:739-743
62. White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, Anstee D, Collinge J, Hawke S (2003) Monoclonal antibodies inhibit prion replication and delay the development of prion disease. *Nature* 422:80-83
63. Doh-Ura K, Iwaki T, Caughey B (2000) Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. *J Virol* 74:4894-4897
64. Korth C, May BC, Cohen FE, Prusiner SB (2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. *Proc Natl Acad Sci USA* 98:9836-9841
65. Turnbull S, Tabner BJ, Brown DR, Allsop D (2003) Quinacrine acts as an antioxidant and reduces the toxicity of the prion peptide PrP106-126. *Neuroreport* 14:1743-1745
66. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters CL (2002) Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. *Ann Neurol* 52:503-506
67. Barret A, Tagliavini F, Forloni G, Bate C, Salmona M, Colombo L, De Luigi A, Limido L, Suardi S, Rossi G, Auvre F, Adjou KT, Sales N, Williams A, Las-